Posts

Fun and games at Oslo Cancer Cluster's summer party, where the 14 new members presented themselves to the cluster.

Meet Our New Members – Part Two

We are proud to introduce Oslo Cancer Cluster’s new members. This is the second part of two stories about our new members.

You can find the first part HERE.

On the 24th of August, Oslo Cancer Cluster hosted a bustling summer party in the Oslo Cancer Cluster Incubator, where the new members had the chance to introduce their amazing work.

This is a brief introduction to those of the new members who primarily work in consulting.

Dehns
At Dehns, they have a commercially focused and practical approach to intellectual property that helps them to turn inspired thinking into patents, registered designs and trade marks. Dehns was founded in 1920 and has over 90 staff members, with offices in multiple locations across England. Dehns is one of the largest firms of trade mark and patent attorneys in Europe.

– Partnering with Oslo Cancer Cluster will allow us at Dehns to have more contact with the diverse members at Oslo Cancer Cluster that could benefit from our services. Norway is a buzzing place for opportunity, so we believe this is a special chance to be more present. By doing this, we hope to help companies with whatever questions or problems they might have, whilst also setting sights on getting in contact earlier, so that we can get to the root of the problem quicker and make a real impact as a result. Undoubtedly, getting to the root of the problem at the start is more exciting for everyone, and we aim to do just that, says Barbara Rigby, associate at Dehns.

GIAMAG
GIAMAG was established in 2012 as a commercial spin-off of Norway’s Institute for Energy Technology (IFE), where their patented technology is based off of the Institute’s research. GIAMAG is not wholly belonging to the area of consulting, but nonetheless offers consulting services in their product: one of the world’s most forceful and configurable magnets. GIAMAG’s mission is to provide solutions based on magnet technology for a varying range of industrial applications. They have the expertise to design and configure magnet systems to customer’s specific requirements.

Acapo
Acapo is an Intellectual Property Rights (IPR) firm mainly focused on the maintanace of patents, trademark registrations and design. Acapo, despite being located in several places, works as one company. The head office is located in Bergen. Acapo has a joint administration with one legal and one patent department. They strive for the highest degree of both service and quality, where the most important assets are their highly qualified professionals and staff members. They do not only offer advice in areas related to Intellectual Property, but also in business areas. Acapo covers all technical fields.

Artemida
Artemida Pharma is a consultancy company in drug development who has highly experienced scientists representing multiple disciplines and therapeutic areas. Artemida Pharma offers optimised strategic drug development for biotechnology and pharmaceutic clients. They have past experience with a wide variety of clients, geographic areas and product types that enable them to offer integrared project-driven solutions.

DNV GL
DNV GL allows organizations to progress the sustainability and safety of their business. They provide classification, technical assurance, software and independent expert advisory services to the maritime, oil & gas and energy industries. They also provide certification services to customers across a wide range of industries. In terms of healthcare, they support organizations in this sector across the globe by applying system thinking to address risks and deliver high-quality, person centered care.

IRW Consulting
IRW is a Nordic Contract Research Organization (CRO) With more than fifteen years of experience in conducting clinical trials, non-interventional studies and medical device studies. They have built a wide network in Scandinavia as well as with the rest of Europe and the United States. IRW, depending on the customer’s requirements, is equipped with staff that is either outsourced or works with in-house projects. They cover all stages of clinical development.

New member Precision Oncology at the summer party. From the left: Patricia Devitt, President, Maureen Higgins, Director of Clinical Operations, Deborah Phippard, Vice-president and Andrea Cotton-Berry, Head of Strategic Operations.

Meet our new members – Part One

We are proud to introduce Oslo Cancer Cluster’s new members. This is the first part of two stories about our new members.

You can find the second part HERE.

On the 24th of August, Oslo Cancer Cluster hosted a summer party with the intention of getting to know their newest members in an informative and fun setting. The party started with a heartfelt welcome and speech held by Oslo Cancer Cluster’s General Manager Ketil Widerberg and intensive mingling amongst guests. After the welcome was in order, each member stood up, in turn, to introduce their amazing work.

Of the 14 new members we have so far this year, here’s an introduction to those who primarily work in the area of biotechnology.

Precision Oncology
Precision Oncology is a specialty contract research organization (CRO) that provides clinical research services. The company primarily provides application of metrics-driven project management to perfect oncology drug development.

As for their inspiration and reasoning for joining the Oslo Cancer Cluster roster of members, Andrea Cotton-Berry, head of Strategic operations at Precision Oncology, responds:

– What really inspires us at Precision Oncology, is matching the right drug to the right patient, by using biomarkers for patient identification and stratification; a true personalized medicine approach, to find more efficient treatments for patients with advanced cancers. We are looking forward to bringing our team of oncology development experts to contribute to the Oslo Cancer Cluster mission and initiatives, especially advancing immuno-oncology research.

Personalis
Personalis is a leading preciscion medicine company focused on advancing next generation sequencing based services for immuno-oncology. The company is mainly focused on producing the most accurate genetic sequence from each sample set, and using analytics and privately owned content to draw reliable and accurate biomedical interpretations of the data.

In regards to current and future inspiration, Erin Newburn, Senior Manager and Field Applications Scientist at Personalis, comments:

– We aspire to utilize next-generation sequencing as a multi-dimensional platform for bio-marker discovery across cancer therapeutics, as well as throughout developmental stages.

iNANOD
iNANOD is a nanotechnology based anti-cancer drug developing company established in 2016. Their goal is to increase efficacy of anti-cancer drugs and to reduce side-effects for cancer patients as well as maximizing the patients longevity. They aim to become a pharmaceutical company for anti-cancer nanomedicines in the near future.

As for expectations and reasoning for joining Oslo Cancer Cluster, Nalinava Sengupta, CEO and Co-Founder of iNANOD shares his view:

– We think our project – to develop cancer nano-medicine – fits best with Oslo Cancer Cluster. In the incubator we get in touch with other similar firms who have achieved milestones in cancer drug delivery. We expect synergistic knowledge transfer within the incubator network, as well as various kinds of help from the cancer research related entrepreneurial ecosystem developed at Oslo Cancer Cluster. This also helps with business developmental aspects and project application writing.

Norgenotech
Norgenotech is a start-up company that originated from the EU project COMICS that aimed at improving production methods for analysis of DNA damage and repair. Norgenotech mainly assesses genotoxicity, or property of chemical agents that damage the genetic information within a cell, as well as drugs. The company also participates in research projects and developing tools for measuring DNA integrity in patients.

Eisai
Eisai AB originates from a global company in Japan that is active in the manufacturing and marketing of pharmaceutical drugs, pharmaceutical production systems, and over-the-counter drugs. Eisai AB, that will be joining the Oslo Cancer Cluster roster of members, is the sales subsidiary of Eisai Company.

Immunitrack
Immunitrack is a startup company with capabilities in production and studies of protein molecules central to the adaptive immune system in humans in order to develop new therapeutics. Their mission is to provide the research community with tools to redesign or select drug candidates at the early stage of research and development, but also to provide reagents to monitor leading drug candidates effect on patient’s immune system.

Nacamed
Nacamed‘s goal is to produce nanoparticles of silicon material for targeted drug delivery of chemotherapy, radiation therapy and diagnostics to kill cancer cells. By using silicon nanoparticles in cases such as therapy, the particles are biodegradable which entails a clean delivery without any side-effects as they completely disappear and dissolve from the body.

Arctic Pharma
Arctic Pharma is a privately held startup biotech company founded in 2012 that primarily focuses on developing innovative anti-cancer drugs. They do this by exploiting cancer cells and their peculiar features, or more specifically, by targeting key enzymes that are upregulated, or have been increased in terms of stimulus with inhibitors designed at Arctic Pharma. Essentially, their main mission is to become a leader in designing cancer therapies that are both environmentally friendly and have few side effects.